Bountiful Approvals May Be Ahead As FDA Starts 2023 With Almost 60 Novel Agents Under Review
The upcoming year could see a rebound approvals if the bigger-than-usual queue of novel agents with 2023 user fee goal dates pans out.
The upcoming year could see a rebound approvals if the bigger-than-usual queue of novel agents with 2023 user fee goal dates pans out.